Table 5 shows that 8e and 8g elicited a significant increase in Bax levels as compared to doxorubicin. 8g demonstrated a comparable induction of Bax (264.90 pg/mL) relative to doxorubicin (276 pg/mL), 32-fold higher than the control untreated breast cancer cell, followed by compound 8e (247.65 pg/mL and 30-fold change). Finally, compound 8g reduced Bcl-2 protein levels in MCF-7 cells to 1.085 ng/mL, followed by compound 8e (1.278 ng/mL) and doxorubicin (0.98 ng/mL). This evidence concerns the gene BCL2 and breast cancer.